Hospital Pharmacy welcomes contributions to this column. Articles originally published in pharmacy department newsletters are reprinted here. Material is selected because of its educational value to pharmacists or because it demonstrates the type of information of interest to newsletter readers. If you wish to have your newsletter material considered for publication in this column, mail a copy—along with a computer disk containing the document—to Neil M. Davis, Editor-in-Chief, Hospital Pharmacy, 1143 Wright Drive, Huntingdon Valley, PA 19006-2721.
Get full access to this article
View all access options for this article.
References
1.
HirshJ., DalenJ.E., AndersonD.R.Oral anticoagulants: Mechanism of action, clinical effectiveness, and optimal therapeutic range.Chest.1998;114 (supp):445S–469S.
2.
MeyerB.M.FDA position on product selection for “narrow therapeutic index” drugs. Am J Health- Syst Pharm.1997; 54: 1630–2.
3.
BenetL.Z., GoyanJ.E.Bioequivalence and narrow therapeutic index drugs. Pharmacotherapy.1995; 15: 433–40.
4.
MeyerB.M.FDA comments on activities in states concerning narrow-therapeutic index drugs. Am J Health-Syst Pharm.1998; 55: 686–7.
5.
WittkowskyA.K.Generic warfarin: Implications for patient care. Pharmacotherapy.1997; 17: 640–3.
6.
HainesS.T.Reflections on generic warfarin. Am J Health-Syst Pharm.1998; 55: 729–33.
7.
PalaretiG., LealiN., CoccheriS.Bleeding complications of oral anticoagulant treatment: An inception-cohort, prospective collaborative study (ISCOAT). Lancet.1996; 348: 423–8.
8.
SawickiP.T.A structured teaching and self-management program for patients receiving oral anticoagulation: A randomized controlled trial. JAMA.1999; 281: 145–50
9.
Warfarin sodium product nonograph. Apothecon; October 1998.
